Skip to main content
. 2023 Dec 7;102(7):549–555. doi: 10.1159/000535599

Table 3.

Correlation between Xerna TME subtypes and other biomarkers

Variable Xerna TME classification P1 P2
IA (n = 4) IS (n = 6) A (n = 5) ID (n = 7) IA + IS (n = 10) A + ID (n = 12)
KRAS status, n (%) 0.848 1.000
 Wild type 7 (32) 1 (25) 2 (33) 1 (20) 3 (43) 3 (30) 4 (33)
 Mutant 15 (68) 3 (75) 4 (67) 4 (80) 4 (57) 7 (70) 8 (67)
PD-L1, n (%) 0.730 1.000
 Negative 10 (48) 2 (67) 2 (33) 3 (60) 3 (43) 4 (44) 6 (50)
 Positive 11 (52) 1 (33) 4 (67) 2 (40) 4 (57) 5 (56) 6 (50)
CD8 expression, n (%) 0.326 0.231
 Low 10 (45) 1 (25) 2 (33) 4 (80) 3 (43) 3 (30) 7 (58)
 High 12 (55) 3 (75) 4 (67) 1 (20) 4 (57) 7 (70) 5 (42)
Treg, n (%) 0.049 0.087
 Low 12 (57) 0 (0) 3 (50) 5 (100) 4 (57) 3 (33) 9 (75)
 High 9 (43) 3 (100) 3 (50) 0 (0) 3 (43) 6 (67) 3 (25)

Xerna TME subtypes: angiogenic (A), immune active (IA), immune desert (ID), and immune suppressed (IS).

P1: comparison among TME subtypes.

P2: comparison between high immune score (IA + IS) and low immune score (A + ID).